Status:
COMPLETED
Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-80 years
Phase:
PHASE3
Brief Summary
This study compares the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 18 weeks, and subjects will visit the clinic 5 times. Subjects will be given...
Detailed Description
Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) "Assessment of the Effect of Addition of Fluticasone Dipropionate to Salmeterol Xinafoate 50µg ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis of COPD.
- Exclusion criteria:
- Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD.
- Other inclusion and exclusion criteria will be evaluated at the first study visit.
Exclusion
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00269126
Start Date
February 1 2005
End Date
August 1 2005
Last Update
April 15 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Kyoto, Japan, 602-8026
2
GSK Investigational Site